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Abstract 125 
Background: Several European countries recently developed international diagnostic and management guidelines 126 
for pemphigus, which have been instrumental in the standardization of pemphigus management,  127 
Objective: We now present results from a subsequent Delphi consensus to broaden the generalizability of 128 
recommendations.  129 
Methods: A preliminary survey, based on the European Dermatology Forum (EDF) and the European Academy 130 
of Dermatology and Venereology (EADV) guidelines, was sent to a panel of international experts to determine 131 
the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in 132 
March 2016 during the annual American Academy of Dermatology (AAD) conference. A second survey was sent 133 
following the meeting to more experts to achieve greater international consensus.  134 
Results: The 39 experts participated in the first round of the Delphi-survey while 54 from 21 countries completed 135 
the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in 136 
Delphi II based on Delphi results and meeting discussion. 137 
Limitations:  Each recommendation represents the majority opinion and therefore may not reflect all possible 138 
treatment options available. 139 
Conclusions: We present here the recommendations resulting from this Delphi process. This international 140 
consensus includes intravenous CD20 inhibitors as a first line therapy option for moderate to severe pemphigus. 141 
142 
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Introduction 143 
Pemphigus encompasses a spectrum of rare mucocutaneous bullous diseases that are autoimmune in 144 
origin. Due to the rarity of these diseases, it can take patients months before being diagnosed with 145 
pemphigus, during which time many are treated for other blistering diseases (1, 2). Even once the 146 
diagnosis is made, treatment regimens can vary greatly as there is no defined standard of care due to the 147 
paucity of large-scale clinical trials evaluating their efficacy (1). 148 
There have been recent national attempts to standardize the diagnosis and management of pemphigus 149 
from individual countries, including the UK, France, Japan, and Germany (3- 6).  However, it was the 150 
European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology 151 
(EADV), which passed the first international guidelines for the management of pemphigus (7). While 152 
these efforts have been instrumental in the standardization of pemphigus management, the lack of 153 
involvement from countries outside of Europe may render these guidelines non-generalizable to other 154 
countries.  155 
In an attempt to garner greater international consensus, the International Bullous Diseases Consensus 156 
Group, convened by Dr. Dedee Murrell and Dr. Victoria Werth, met in March 2016 at the annual 157 
American Academy of Dermatology (AAD) conference in Washington D.C. with the goal of developing 158 
international consensus guidelines for the diagnosis and management of pemphigus vulgaris and 159 
pemphigus foliaceus. Prior to the meeting, members of the group, comprised of blistering disease 160 
experts, completed a Delphi survey based on the EDF/EADV guidelines. Some of the tests and 161 
treatments mentioned may not be available or officially registered in all countries and have been 162 
assessed based on their scientific usefulness rather than regulation status. The Delphi technique is a 163 
consensus-building process in which questionnaires are given to a group of experts in a series of rounds 164 
to ultimately achieve opinion convergence (8). The results of the questionnaire were discussed in the 165 
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meeting and a follow-up survey was sent out to further consensus.   166 
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Methods 167 
The first round of surveys was delivered via email in February 2016 and completed by 39 expert 168 
participants. The results of the survey were tallied and delivered to the group. A median score of 70 169 
percent or greater per question was used as the consensus threshold for agreement, while a median score 170 
of 30 or lower was established as the consensus threshold for disagreement. Statements that achieved 171 
median scores between 30 and 70 were determined as having reached no consensus among participants 172 
and discussed during the meeting. Afterwards, these statements were revised according to the opinion of 173 
the participants and sent out and completed by 54 individuals in the subsequent round. The survey was 174 
designed and distributed using RedCAP software. 175 
 176 
Initial Clinical Presentation of Pemphigus         177 
The initial evaluation of suspected pemphigus should seek to determine the signs or symptoms present 178 
that would corroborate the diagnosis of pemphigus, as well as to screen for possible comorbidities.  179 
Major Objectives 180 
• To verify the diagnosis of pemphigus 181 
• To evaluate possible risk factors, severity factors and comorbidities  182 
• To specify the type of initial involvement (skin, mucosa) and its extent 183 
• To evaluate the prognosis depending on the age of the patient and general condition (Karnovsky 184 
score, optional) 185 
• There are two clinical scores, Pemphigus Disease and Area Index (PDAI) and/or Autoimmune 186 
Bullous Skin Intensity and Severity Score (ABSIS), which are currently being used as clinical 187 
outcome parameters and in clinical trials for the evaluation of the extent and activity of pemphigus. 188 
Presently, there are no agreed upon cutoff values to define mild, moderate, or severe disease for 189 
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either the PDAI or the ABSIS; however, there have been two studies which have attempted to 190 
define these values. In one multicenter study based in Japan, researchers evaluated both newly 191 
diagnosed as well as relapsing pemphigus patients and determined PDAI cutoff values of 0-8 for 192 
mild, 9-24 for moderate, and ≥25 for severe disease (9). Another multicenter study, conducted 193 
internationally, assessed only patients with newly diagnosed pemphigus and determined cut-off 194 
values of 15 and 45 for PDAI and 17 and 53 for ABSIS, to distinguish between mild, moderate and 195 
severe (significant and extensive) forms of pemphigus (10). While these studies greatly add to our 196 
understanding of disease activity scoring, it is premature to definitively state cutoff values presently.  197 
Specialists Involved 198 
The management of patients with pemphigus is the responsibility of dermatologists with experience 199 
in treating bullous diseases. If extensive, the initial management of the disease usually requires 200 
hospitalization until clinical control of the bullous eruption is achieved. In limited forms of 201 
pemphigus, additional diagnostic examinations and clinical monitoring can be done in either an 202 
inpatient or outpatient setting. 203 
The overall disease management is coordinated by the dermatologist with the cooperation of the 204 
referring dermatologist/family practitioner, the general physician and other medical specialists and 205 
hospital doctors from the center of reference and/or geographical area (if a reference center exists in 206 
the particular country).  207 
Rarely, the disease can occur during childhood, and children should be managed by a 208 
multidisciplinary team, jointly by a reference center, a pediatric dermatology department or a 209 
pediatrician. 210 
Other health professionals who may serve as supportive adjuncts are as follows: 211 
• The referring dermatologist  212 
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• The patient’s primary care provider to manage comorbidities and monitor for treatment side-213 
effects 214 
• Other specialists whose expertise is necessary, based on comorbidities and/or mucosal locations of 215 
pemphigus, such as internists, cardiologists, stomatologists, ophthalmologists, 216 
otorhinolaryngologists, gastroenterologists, gynecologists, urologists, proctologists, 217 
rheumatologists, oncologists, dieticians, physiotherapists and psychologists 218 
• Home health nurses, where available, in selected cases in which home care is required and 219 
applicable, e.g. elderly or disabled patients with residual mucosal or skin lesions following 220 
hospitalization 221 
• Nurse specialist/practitioner to aid in the management of stable patients, making phone calls, or 222 
changing wound dressings.  223 
Diagnosis 224 
The diagnosis of pemphigus is based on the following criteria:  225 
• Clinical presentation  226 
• Histopathology 227 
• Direct immunofluorescence microscopy (DIF) of perilesional skin 228 
• Serological detection of serum autoantibodies against epithelial cell surface by indirect 229 
immunofluorescence microscopy (IIF) and/or enzyme-linked immunosorbent assay (ELISA) 230 
• Diagnosis requires clinical presentation and histopathology that are consistent with pemphigus 231 
and either a positive DIF or serological detection of autoantibodies against epithelial cell surface 232 
antigens. 233 
Clinical Evaluation 234 
Medical History 235 
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• Timing of symptoms 236 
• Functional symptoms, i.e. pain, pruritus, intensity of dysphagia, ocular and ENT symptoms, 237 
dysuria, anogenital problems and weight loss 238 
• Contraindications of systemic corticosteroid treatment and developing complications of 239 
immunosuppressive treatments 240 
• Contraception and plans for pregnancy in women of child bearing potential 241 
• Medication history with special attention to causes of drug-induced pemphigus, including D-242 
penicillamine, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and 243 
cephalosporins,  244 
• Psychological tolerance of possible side-effects due to treatment, especially corticosteroids 245 
• Quality of life impact due to disease burden 246 
Physical examination          247 
• Extent of skin and mucosal lesions and the degree of disease damage  248 
• Patient’s overall state of health and comorbidities: 249 
 General condition (Karnovsky index) 250 
 Weight 251 
  Vital signs, including blood pressure and temperature 252 
 Comorbidities (neoplastic, cardiovascular, musculoskeletal, etc.) 253 
 254 
The changes from the European guidelines are summarized in the supplementary material.  255 
The laboratory work up is delineated in Table 1.  256 
Therapeutic Management 257 
Objectives 258 
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• To promotehealing of blisters and erosions 259 
• To improve functional status 260 
• To prevent/strictly limit development of new blisters and erosions 261 
• To improve the quality of life  262 
• To limit common side-effects usually associated with long-term immunosuppressive or 263 
corticosteroid treatment 264 
First-Line Treatment  265 
The dosing of specific medications is delineated in Table 2.  266 
• Corticosteroids 267 
• Anti-CD20 monoclonal antibodies  268 
Corticosteroid-Sparing Agents 269 
First-Line Corticosteroid-Sparing Agents  270 
• Azathioprine 271 
• Mycophenolate mofetil or mycophenolic acid  272 
Other Corticosteroid-Sparing Agents 273 
• Intravenous immunoglobulins (IVIG) 274 
• Immunoadsorption 275 
• Cyclophosphamide 276 
Supportive treatment that may be recommended: 277 
• Proper dental care   278 
• Intralesional injections of corticosteroids (triamcinolone acetonide) for isolated lesions. 279 
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• Topical treatment with potent corticosteroids (clobetasol propionate) or calcineurin inhibitors 280 
applied directly to the lesions, and oral topical corticosteroids (such as triamcinolone acetonide 281 
gel) directly to oropharyngeal erosions for use in combination with systemic therapy 282 
• Antiseptic baths  283 
• Covering erosive lesions, if present, using low adhesive wound dressings or local emollients, and 284 
compresses. 285 
• Analgesics (over the counter analgesics and opioids) 286 
• Gels containing local anesthetics for application at the mucosal surfaces.  287 
• Nutritional management with the help of a dietician or a nutritionist if malnutrition is related to 288 
oral involvement or systemic corticosteroid therapy 289 
Prophylaxis against Side Effects in Prolonged Corticosteroid Therapy 290 
• Osteoporosis baseline screening and prophylaxis 291 
• Ophthalmologic evaluation 292 
• Vitamin D and calcium supplementation at initiation of corticosteroids treatment 293 
• Treatment with bisphosphonates (i.e. alendronate, risedronate) in patients at risk (post-menopausal 294 
women and men >50 years who will be on corticosteroid treatment > 3 months) of developing 295 
osteoporosis 296 
• Systemic antifungals, antiviral and antibiotic treatment should be used when clinically indicated 297 
• H2-blockers or proton pump inhibitor use should be individualized to the patients given lack of 298 
sufficient evidence.  299 
• Anti-thrombotic prophylaxis in case of high risk of thrombosis 300 
• Psychological support if required 301 
• Physiotherapy if prolonged corticosteroid therapy is required 302 
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Vaccinations 303 
• Adjuvant immunosuppressants and intravenous CD20 inhibitors contraindicate the use of live 304 
vaccines.  305 
• Patients receiving oral corticosteroids or immunosuppressive therapy may be vaccinated against 306 
seasonal influenza, H1N1, tetanus and pneumococci. The level of protection is questionable during 307 
systemic immunosuppression.  308 
Monitoring 309 
Objectives 310 
• To evaluate the efficacy and safety of treatment 311 
• To plan the gradual reduction of immunosuppressive treatment, and the duration of maintenance 312 
therapy or its discontinuation   313 
Definitions for Disease Outcome Parameters (12) 314 
• Control of disease activity: The time at which new lesions cease to form and established lesions 315 
begin to heal 316 
• End of consolidation phase: The time at which no new lesions have developed for a minimum of 2 317 
weeks and approximately 80% of lesions have healed.  This is when most clinicians start to taper 318 
steroids." 319 
• Complete remission on therapy: The absence of new or established lesions while the patient is 320 
receiving minimal therapy 321 
• Complete remission off therapy: The absence of new and/or established lesions while the patient 322 
is off all systemic therapy for at least 2 months 323 
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• Relapse/flare: Appearance of ≥3 new lesions/month that do not heal spontaneously within 1 week, 324 
or by the extension of established lesions, in a patient who has achieved disease control 325 
• Minimal therapy: Prednisolone (or the equivalent) at ≤10 mg/day and/or minimal adjuvant therapy 326 
for at least 2 months 327 
Approach to Be Maintained After Consolidation Phase 328 
• Expect slow clinical improvement, often requiring a period of 1–3 months for complete healing of 329 
lesions 330 
• Start tapering steroids as soon as disease control is reached or up to the end of consolidation phase 331 
• Decrease predniso(lo)ne by 25% every two weeks, until 20 mg per day. Once at 20 mg per day, 332 
decrease predniso(lo)ne by 2.5 mg a week; and then at 10 mg/day, decrease dose by 1 mg per day 333 
after that. 334 
• Go back to last dose if >3 lesions reappear during the tapering of oral corticosteroid therapy 335 
• If relapse occurs (i.e the appearance of ≥3 new lesions/month that do not heal spontaneously 336 
within 1 week, or there is extension of established lesions), increase the oral corticosteroid dose by 337 
going back to the second to last dose until control of the lesions is achieved within 2 weeks, then 338 
resume taper. 339 
•  If disease control is still not reached despite this, go back to initial dose. 340 
 If oral corticosteroids are given alone: add an immunosuppressant (especially in case of 341 
early-stage relapse occurring despite continued high-dose corticosteroid treatment)  342 
 If oral corticosteroids are already combined with an immunosuppressant, consider a change 343 
in immunosuppressant  344 
Scheduling and Content of Consultations 345 
The frequency of consultations (physical exam, additional exams) depends on:  346 
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• The patient’s clinical condition including comorbidities 347 
• The severity and disease course specific to the patient’s pemphigus during treatment 348 
• The therapeutics used (monitoring, tolerance, side-effects)  349 
• The level of disease activity measure by the ABSIS and/or PDAI, (optional) 350 
Initially, follow-up visits should be offered every two weeks until clinical disease control is achieved. In 351 
the consolidation phase, patients should be seen every 1-2 weeks in order to determine how soon 352 
patients could be started on a steroid taper. Then, during tapering phase, for the next 3 months, monthly 353 
clinical follow-ups are recommended. Once in partial or complete remission on minimal therapy, visits 354 
can be less frequent, such as every 3 months.  355 
Clinical Evaluation 356 
The clinical follow-up should seek to clarify:  357 
• Level of disease control 358 
• Presence of adverse effects due to treatment including: 359 
 Diabetes, high blood pressure, cardiac insufficiency, myopathy, osteoporosis, avascular bone 360 
necrosis, glaucoma, cataract due to corticosteroids 361 
 Infections, notably respiratory, hepatitis, or hematological abnormalities (leucopenia) as a 362 
result of immunosuppression  363 
 Mental disorders  364 
Serological Monitoring Of Disease Activity 365 
Determination of serum autoantibodies at the initiation of treatment, after 3 months and every 3–6 366 
months based on the evolution, or in case of relapse by:  367 
• ELISA: anti-Dsg1 and/or Dsg3 IgG 368 
• If ELISA is not available: IIF microscopy utilizing monkey esophagus 369 
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• Overall, serum concentrations of IgG autoantibodies against Dsg1 and Dsg3 correlate with the 370 
clinical activity of pemphigus and may thus help in therapeutic decision making 371 
• The persistence of high levels of anti-Dsg1 by ELISA has a positive predictive value for skin 372 
relapses, whereas the persistence of anti-Dsg3 IgG does not necessarily indicate a mucosal relapse 373 
Discontinuation of Treatment 374 
• Discontinuation of treatment is primarily based on the clinical symptoms but may be also 375 
supported by the findings of Dsg ELISA, IIF and/or negative DIF microscopy of a skin biopsy. 376 
• Discontinuation of systemic corticosteroids may be proposed in patients in complete remission on 377 
minimal therapy (prednisolone or equivalent at ≤10 mg/day). The adjuvants may be stopped 6–12 378 
months after achieving complete remission on minimal therapy with adjuvants only.    379 
Possible Sequelae 380 
• Pemphigus may cause permanent sequelae not only due to the involvement of skin and mucosa 381 
but also due to treatment side effects, justifying request for recognition or help from departmental 382 
disability centers where available. The extent of immunosuppressive therapy increases the risk of 383 
side-effects.  384 
 385 
Information for patients and their families 386 
• Education about the disease, its clinical course and prognosis, treatment, relapse signs, and 387 
possible side-effects of treatment.  388 
• Awareness of self-support groups, which may help disseminate information regarding the disease, 389 
provide comfort and share the experience of patients regarding daily life. Additionally, it may 390 
contribute to a better overall management of the disease by promoting cooperation between 391 
patients, patient associations and health professionals.  392 
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• Information about referral centers 393 
• Education about triggers such as drugs, operations, radiation and physical trauma 394 
• Counseling on dietary restrictions not necessary due to insufficient evidence 395 
Areas for Future Studies 396 
These recommendations are a working document whose purpose is to provide clinicians the most up-to-397 
date consensus on the diagnosis and management of pemphigus. Further studies are needed to clarify 398 
optimal therapeutic regimens and describe their safety and efficacy in the treatment of pemphigus. Some 399 
areas identified by the authors include: 400 
Intravenous CD20 inhibitors 401 
• Although a recent clinical trial has demonstrated superior efficacy and safety of the intravenous 402 
CD20 inhibitor, rituximab, with short term lower doses of corticosteroids than standard dose 403 
systemic corticosteroids initially with slow tapering (9), several questions remain about how best to 404 
use it:  405 
 How should other medications be combined with intravenous CD20 inhibitors? 406 
 Should corticosteroids be used in combination with intravenous CD20 inhibitors from the 407 
start to gain disease control and reduce unnecessary iatrogenic morbidity for patients? 408 
 In some patients with comorbidities or mild disease, can CD20 inhibitors be used alone or 409 
with a topical corticosteroid?  410 
 What is the role of other immunosuppressives, IVIG, immunoadsorption, etc., along with 411 
CD20 inhibitors?  412 
• Dosing of CD20 inhibitors 413 
 Is there a specific disease activity level in which patients can be treated with only oral 414 
steroids and not necessarily CD20 inhibitors? 415 
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 What is the ideal threshold in patients on systemic corticosteroids or immunosuppressants to 416 
begin CD20 inhibitor therapy? 417 
 What is the optimal dose, frequency, total number of maintenance infusions to use?  418 
 Are these drugs indicated in patients with negative anti-DSG antibodies? 419 
 In cases of relapse, is a single dose of 1000mg/infusion of rituximab (or 375 mg/m2 in 420 
lymphoma protocol) enough to achieve remission instead of a full dose cycle of rituximab (2 421 
x 1000 mg 2 weeks apart or 4 x 375 m2/week)?  422 
• Long term side effects 423 
 Will more side effects occur when more patients are treated with multiple maintenance 424 
infusions of CD20 inhibitors?   425 
Other treatment options 426 
• What role do other treatment options, like plasmapheresis, play in the treatment of pemphigus? 427 
 428 
Conclusion 429 
In summary, we present here the recommendations arising from a Delphi process involving 39 430 
pemphigus experts.  We make recommendations for evaluation and treatment of pemphigus, including 431 
initial evaluation, diagnosis, and management, as well as strategies for maintenance therapy and tapering 432 
of medications in remission. 433 
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Table 1: Laboratory Work-up 479 
Histopathology 
• A biopsy should be taken of a recent (<24 h) small vesicle or 1/3 of the peripheral 
portion of a blister and 2/3 perilesional skin (placed in 4% formalin solution) for 
routine histopathological analysis: intraepidermal suprabasal acantholysis in PV or 
acantholysis at the granular layer in PF. 
 Direct immunofluorescence microscopy (DIF)  
• Skin biopsy of perilesional skin (up to 1 cm from a recent lesion), put into a 
cryotube for transportation in saline (delivery <36 h) in a cylinder of liquid nitrogen 
or Michel’s fixative for DIF analysis:  
 DIF: IgG and/or C3 deposits at the surface of epidermal keratinocytes. The 
smooth and reticular staining pattern is also referred to as ‘chicken wire’, 
‘honeycomb’ or ‘fishnet-like’. 
 IgA deposits with an epithelial cell surface pattern in addition to IgG may be 
present in a subset of cases.  
 Epithelial cell surface deposits may be associated with linear or granular 
deposits of IgG or C3 along the dermal–epidermal junction, suggestive of 
other autoimmune blistering diseases including paraneoplastic pemphigus or 
pemphigus erythematosus, or the coexistence of pemphigus and pemphigoid 
Immune serological tests         
Indirect immunofluorescence microscopy (IIF)  
• IIF test on monkey esophagus or human skin to search for autoantibodies against 
surface proteins of epidermal keratinocytes, similar to the pattern seen on DIF. 
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• In case of atypical presentation or the suspicion of another autoimmune bullous 
disorder, additional immunopathological tests may be performed, such as IIF on rat 
bladder and immunoblot/immunoprecipitation 
• IIF on human cells with recombinant expression of desmoglein 1, desmoglein 3 or 
envoplakin (Euroimmun) is an alternative where desmoglein- or envoplakin-specific 
ELISA cannot be used  
ELISA 
• Detection of anti-desmoglein 1 (Dsg1) (PF/mucocutaneous PV) and/or anti-
desmoglein 3 (Dsg3) IgG autoantibodies (mucosal  or mucocutaneous PV) by ELISA 
(MBL, Euroimmun) 
• The detection of IgG autoantibodies by ELISA is positive in more than 90% of 
cases 
• In general, the ELISA index correlates with the extent and/or activity of disease 
(see remark above) and prognostic value for relapse, helping to guide treatment. 
Large prospective cohort studies are, however, missing in this context to provide 
reliable data about predictive value  
Work-Up before Corticosteroid or Immunosuppressive Therapy 
• Complete blood count 
• Creatinine, blood electrolytes 
• Transaminases, gamma GT, alkaline phosphatase 
• Total serum protein, albumin 
• Fasting serum glucose 
• Hepatitis B, C and HIV 
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• Quantiferon gold or PPD is recommended 
Recommended, on indication or optional:  
• Serum IgA deficiency should be ruled out prior to IVIG treatment 
• Analysis of thiopurine methyltransferase (TPMT) activity is recommended when 
azathioprine is considered in countries where genetic polymorphisms for decreased 
TMPT activity levels are more common 
• Chest X-ray if Quantiferon gold or PPD is abnormal 
• ß HCG is recommended to exclude pregnancy in women of childbearing potential 
• Osteodensitometry is recommended prior to corticosteroid treatment 
• Ocular examination (glaucoma, cataract) is recommended  
 480 
481 
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Table 2: Medication Dosing 482 
First-Line Treatment  
Corticosteroids 
• Systemic corticosteroid therapy (predniso(lo)ne at 0.5 mg to 1.5 mg/kg/day)  
• Systemic corticosteroids (oral or intravenous pulses) can be combined with an 
immunosuppressive adjuvant at the onset of therapy, especially in cases of increased risk of 
corticosteroid therapy, complications due to expected prolonged use (>4 months) or dose 
dependency above minimal therapy (>10 mg/day). However, there is limited evidence that 
the addition of adjuvants is superior to treatment with corticosteroids alone. 
• While limited, studies have not shown IV corticosteroid pulses to have an additional 
benefit on top of conventional first-line treatment with oral predniso(lo)ne and 
immunosuppressive adjuvants. While more evidence is needed, steroid pulse therapy in 
addition to conventional treatment should be reserved for refractory cases of pemphigus. 
• Treat with the smallest dose for the shortest time possible to minimize risk of adverse 
events 
Anti-CD20 monoclonal antibodies  
Currently there are two intravenous CD20 inhibitors available, rituximab and ofatumumab. All 
the published trials so far have used rituximab.  
• First line treatment in new onset moderate to severe pemphigus and/or for patients who do 
not achieve clinical remission with systemic corticosteroids and/or immunosuppressive 
adjuvants (11). Allows for more rapid tapering of corticosteroid doses and a major 
corticosteroid sparing effect. 
• A course of intravenous rituximab consists of 2 x 1000 mg (2 weeks apart) or 4 x 375 
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mg/m2 (1 week apart).  
• Treatment can be repeated in case of clinical relapse or as early as 6 months after treatment. 
Lower doses are sometimes used for retreatment. 
• Combine with short-term (<4 months) systemic corticosteroids and long-term (>12 months) 
immunosuppressive treatment, although the need for immunosuppressive adjuvants in 
rituximab therapy remains unclear. 
• The incidence of unforeseen fatal infections such as progressive multifocal 
leukoencephalopathy (PML) cannot be estimated due to the rarity of pemphigus. 
Corticosteroid-Sparing Agents 
First-Line Corticosteroid-Sparing Agents  
• Azathioprine (1–3 mg/kg/day).  
 Start first week 50 mg/day to detect idiosyncratic reactions such as sudden onset 
fevers, oral ulcers, elevated liver function tests and/or DRESS (and in case stop 
immediately), and then raise to desired dose. Although not predictive for idiosyncratic 
reactions, TPMT activity should be evaluated in countries/ethnicities where there is a 
higher incidence of polymorphisms before commencing therapy because 
recommended azathioprine doses vary based upon TPMT activity. In general, adults 
with pemphigus and high TPMT activity are treated with normal doses of azathioprine 
(up to 2.5 mg/kg/day). Patients with intermediate or low TPMT activity should receive 
a lower maintenance dose (up to 0.5 to 1.5 mg/kg/day) depending on level of enzyme 
activity. Patients that lack TPMT activity should avoid treatment with azathioprine.  
• Mycophenolate mofetil (30 mg/kg-45 mg/kg/day) or mycophenolic acid (1440 mg/day).  
Other Corticosteroid-Sparing Agents 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
29
• Intravenous immunoglobulins (IVIG) (2g/kg over 2-5 days per month) 
 Treatment is generally combined with systemic corticosteroids (initially) and 
immunosuppressive adjuvants 
 Treatment should be performed over several days to avoid side-effects 
 Aseptic meningitis is a rare but important side-effect of IVIG treatment which needs to 
be kept in mind in patients who commonly experience episodes of migraine 
 Although uncommon, patients with IgA deficiency should receive IgA-depleted IVIG 
treatment. 
• Immunoadsorption 
 First-line treatment option in emergency situations where available  
 Second-line corticosteroid sparing agent where available 
 Contraindications include severe systemic infections, severe cardiovascular diseases, 
hypersensitivity against components of the immunoadsorption column, treatment with 
angiotensin-converting enzyme inhibitors and extensive hemorrhagic diathesis 
• Cyclophosphamide 
 Use in cases of limited resources or in severe cases that have not responded to other 
treatments 
 Use as a drug of last resort due to long-term side effects 
 483 
484 
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 485 
Figure 1: Diagnosis of Pemphigus 486 
Diagnosis requires clinical presentation and histopathology that are consistent with pemphigus 487 
and either a positive DIF or serological detection of autoantibodies against epithelial cell surface 488 
antigens.489 
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 490 
Figure 2: Treatment Options 491 
The principal objective is to promote the healing of blisters and erosions, prevent development of new 492 
lesions, and minimize serious side effects of treatment. 493 
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Table 1:Summary of the changes made to previous guidelines 
The following is a summary of the differences with the EDF/EADV guidelines.  
• The following set of guidelines was revised to include diagnostic and management 
interventions for pemphigus vulgaris (PV) and pemphigus foliaceus (PF) only. 
• The roles of general practitioners, nurse practitioners, and home care health nurses 
were defined. 
• The titles “first-line” and “second-line” adjuvants were changed to “first-line 
corticosteroid sparing agents” and “other corticosteroid sparing agents”.  
• Intravenous CD20 inhibitors were added as a first-line treatment recommendation 
for moderate to severe pemphigus 
• The following qualifying statement was added to the recommendation regarding 
analysis of thiopurine methyltransferase (TPMT) activity when azathioprine is 
considered: “in countries where genetic polymorphisms for decreased TMPT activity 
levels are more common.” 
• “In case of elevated risk” was removed as a qualifying statement with regards to 
checking a Quantiferon or purified protein derivative (PPD) skin test to rule out 
tuberculosis prior to initiating treatment. 
• Statements of facts as opposed to recommendations were removed.  
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Capsule summary 1 
• The European Dermatology Forum and the European Academy of Dermatology and 2 
Venereology (EDF/EADV) passed management guidelines for pemphigus.  3 
• We present the recommendations of international experts, which have resulted from 4 
a Delphi consensus gathering exercise based on the EDF/EADV guidelines.  5 
• This international consensus includes intravenous CD20 inhibitors as a first line 6 
therapy option for moderate to severe pemphigus. 7 
